BACKGROUND AND AIM: Probiotics might offer an attractive alternative for standard antibiotic therapy to treat Clostridium difficile infections (CDI). We specifically selected a Bacillus amyloliquefaciens strain for its high in vitro antibacterial activity against C. difficile and tested its efficacy to prevent CDI in a mouse model. METHODS: B. amyloliquefaciens supernatant was tested against a large collection of C. difficile strains using an agar well diffusion test. B. amyloliquefaciens was orally administered to C57BL/6 mice in which CDI was induced using C. difficile VPI 10463, and its effect was compared with control mice receiving no treatment and mice receiving Saccharomyces boulardii. Mice were followed up daily for signs of disease including weight loss. At necropsy, the colon was collected and subjected to histopathological analysis. C. difficile toxin A/B levels and colon weight/length and colon/body weight ratios were calculated. RESULTS: B. amyloliquefaciens supernatant was able to inhibit the growth of all C. difficile strains. Results of the in vivo trial indicated a significant weight loss for untreated and S. boulardii-treated mice as compared to B. amyloliquefaciens-treated mice. C. difficile toxin A and B levels were significantly higher for untreated and S. boulardii-treated mice than B. amyloliquefaciens-treated mice. A significantly lower degree of colon damage was detected for B. amyloliquefaciens-treated mice as compared to untreated and S. boulardii-treated mice, based on histopathological analysis, colon weight/length and colon/body weight ratios. CONCLUSION: Administration of B. amyloliquefaciens was successful in preventing CDI in a mouse model.
BACKGROUND AND AIM: Probiotics might offer an attractive alternative for standard antibiotic therapy to treat Clostridium difficile infections (CDI). We specifically selected a Bacillus amyloliquefaciens strain for its high in vitro antibacterial activity against C. difficile and tested its efficacy to prevent CDI in a mouse model. METHODS:B. amyloliquefaciens supernatant was tested against a large collection of C. difficile strains using an agar well diffusion test. B. amyloliquefaciens was orally administered to C57BL/6 mice in which CDI was induced using C. difficile VPI 10463, and its effect was compared with control mice receiving no treatment and mice receiving Saccharomyces boulardii. Mice were followed up daily for signs of disease including weight loss. At necropsy, the colon was collected and subjected to histopathological analysis. C. difficile toxin A/B levels and colon weight/length and colon/body weight ratios were calculated. RESULTS:B. amyloliquefaciens supernatant was able to inhibit the growth of all C. difficile strains. Results of the in vivo trial indicated a significant weight loss for untreated and S. boulardii-treated mice as compared to B. amyloliquefaciens-treated mice. C. difficile toxin A and B levels were significantly higher for untreated and S. boulardii-treated mice than B. amyloliquefaciens-treated mice. A significantly lower degree of colon damage was detected for B. amyloliquefaciens-treated mice as compared to untreated and S. boulardii-treated mice, based on histopathological analysis, colon weight/length and colon/body weight ratios. CONCLUSION: Administration of B. amyloliquefaciens was successful in preventing CDI in a mouse model.
Authors: Michelle M O'Donnell; James W Hegarty; Brian Healy; Sarah Schulz; Calum J Walsh; Colin Hill; R Paul Ross; Mary C Rea; Ronald Farquhar; Laurent Chesnel Journal: Sci Rep Date: 2022-06-03 Impact factor: 4.996
Authors: Marie Christine Uwamahoro; Richard Massicotte; Yves Hurtubise; François Gagné-Bourque; Akier Assanta Mafu; L'Hocine Yahia Journal: Front Public Health Date: 2018-02-05
Authors: Jia Lv; Rong Da; Yue Cheng; Xiaohong Tuo; Jie Wei; Kaichong Jiang; Adediji Omolade Monisayo; Bei Han Journal: Biomed Res Int Date: 2020-03-03 Impact factor: 3.411